Analysis of data for clinical response was based on an intent-to-treat population including all patients who received at least one dose of study drug, entering each part of the study.
All outcomes were assessed based on an intent-to-treat analysis in the 6-month follow-up period.
Based on an Intent-to-treat analysis, the overall response rate was 35.0%.
The OS data is based on an intent-to-treat analysis, independent of cross-over status at week 16.
The results were reported based on an intent-to-treat analysis (last observation carried forward) for both depression and diabetes outcomes.
Analyses are based on an intent-to-treat approach, with children analyzed based on their enrollment in a given program model.
We have observed a favorable OS (based on an intent-to-treat analysis) of 51.6 months, and 5 liver resections (4 laparotomies) were avoided.
Based on an intent-to-treat analysis, the overall response rate was 19% in the RT-5-FU arm, 22% in the RT-GC arm, and 13% in patients randomised to RT-GC+GC.
In a double-blind randomized clinical trial, rivaroxaban was shown to have similar efficacy in stroke prevention as warfarin based on an intent-to-treat analysis, but superior efficacy and similar risk of major bleeding compared to warfarin based on a per protocol analysis [ 5].
Based on an intent-to-treat analysis of all women who were randomized and an assumption of no completion of follow-up exam for women with missing outcome data, self-reported completion of follow-up was 61% in the intervention arm and 46% in the usual care control arm (p < 0.069).
Based on an intent-to-treat analysis of all women who were randomized and an assumption of no completion of follow-up exam for women who refused participation, could not be contacted or dropped out, self-reported completion of follow-up was 61% in the intervention arm and 46% in the control arm (p < 0.069).
